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1. Introduction 
Neuroblastoma is a solid tumor cancer that originates in the nerve tissue of the neck, chest, 
abdomen, or pelvis, but most commonly in the adrenal gland. It is the third most common 
pediatric cancer and accounts for ~15% of all childhood cancer deaths. Neuroblastoma has 
one of the lowest survival rates of all pediatric cancers. It is the most common solid tumor 
diagnosed during infancy. This tumor may involute spontaneously in infants, or it may 
sometimes mature to a benign ganglioneuroma. On the other hand, older children often 
present with advanced stage disease at the time of diagnosis. While survival in patients with 
favorable biological features may exceed 90%; the survival rates for children with high risk 
neuroblastoma have historically been under 40%. However, advances made in recent years 
in understanding the biology of neuroblastoma have led to the identification of patient 
groups with higher risk disease and to the rise of new modalities for combating this disease. 
Patients with high-risk neuroblastoma undergo aggressive multi-modal therapies including, 
chemotherapy, immunotherapy, surgery, stem cell transplantation, and radiation. Survivors 
also experience many treatment related toxicities and long term side effects. Therefore, new 
approaches are needed for these patients (Maris, 2010) 
One of the molecules that can stimulate differentiation of neuroblastoma cells is Ceramide 
(Fig. 1), a biologically active effector molecule composed of a fatty acyl chain bound to a 
sphingoid backbone via an amide linkage (Kraveka & Hannun, 2009). The study and 
modulation of sphingolipids and their effects has emerged as an attractive therapeutic target 
due to their potent anti-proliferative effects (Hannun & Obeid, 2008). Ceramide is the central 
building block for sphingolipids. It serves as a precursor for the synthesis of more complex 
sphingolipids, and is generated by multiple pathways (Fig. 2). Sphingolipids comprise a 
class of lipids that share the presence of a sphingosine (or related sphingoid) base in the 
backbone of their structures. Research in the past two decades has shown that 
sphingolipids, in addition to their roles as structural components of cell membranes, play 
important roles as regulators of signal transduction in cell differentiation, cell proliferation, 
inflammation and apoptosis. Ceramide mediates important cellular activities such as 
induction of cell differentiation, growth arrest, senescence, and apoptosis. Sphingosine-1-
phosphate has the opposite effect of ceramide stimulating cell proliferation and is involved 
in angiogenesis and inflammation (Kolesnick, 2002). In this chapter we will review the roles 
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these bioactive sphingolipids and their related enzymes play in cancer pathogenesis and 
how their regulation is a novel target for neuroblastoma therapy. 
2. Sphingolipids 
2.1 Background 
Sphingolipids were first discovered in the late 1800s. Sphingolipids such as cerebroside and 
sphingomyelin were first isolated from brain tissues by J. L. W. Thudichum (van Echten-
Deckert & Herget, 2006). He named these compounds after the Sphinx because of their 
enigmatic properties. For a long time, sphingolipids had been identified as biologically inert 
components of cell membranes. However, advances in biochemistry and molecular biology 
have demonstrated that these lipids play key roles in the regulation of several fundamental 
biological processes such as signal transduction, cell proliferation, migration, and apoptosis 
(Ogretmen & Hannun, 2004). These regulations are mediated by many enzymes involved in 
sphingolipid metabolism (Hannun & Luberto, 2000).  
2.2 Structure and metabolism of sphingolipids 
Sphingolipids are composed of a long chain sphingoid base that is acylated with a fatty acid 
via an amide linkage, and a polar head group (Fig 1.). In contrast to ceramide, complex 
sphingolipids contain hydrophilic groups such as phosphate, phosphocholine, or sugar 
residues. Based on the head group, sphingolipids may be divided into three groups: 
ceramides, sphingomyelins, and glycosphingolipids. Ceramide is the central building block 
for sphingolipids and has a hydroxyl group at position 1, sphingomyelin has 
phosphocholine, and glycosphingolipids have carbohydrate groups. The latter are further 
subdivided into cerebrosides, gangliosides, and sulfatides (Jana & Pahan, 2010; Sietsma et 
al., 2002). Gangliosides, such as GD2, are composed of a gylcosphingolipid (ceramide and 
oligosaccharide) with one or more sialic acids such as n-acytlneuraminic acid liked to the 
sugar.  
The metabolic pathways of sphingolipids are very complex (Fig 2.). Sphingolipid metabolism 
is regulated at several different levels such as the expression of regulating enzymes, post-
translational modifications, or allosteric mechanisms (Futerman & Hannun, 2004). There are 
multiple pathways for the generation and regulation of bioactive Sphingolipids (Figure 2). 
Many of these pathways reside in specific sub-cellular compartments and respond to various 
extra- and intra-cellular stimuli. Most enzymes of sphingolipid metabolism have specific sub-
cellular localization(s), thereby exerting profound effects on the signaling and regulatory 
functions of the generated sphingolipid in a specific compartment. The best studied of these 
pathways are the de-novo pathway, the sphingomyelinase pathway, and the salvage/recycling 
pathway (Kraveka & Hannun, 2009).  
The de-novo pathway pathway of ceramide synthesis starts at the cytosolic surface of the 
endoplasmic reticulum (ER) where a series of enzymes generate ceramides with different 
acyl chain lengths from non-sphingolipid precursors (Futerman & Hannun, 2004; Gault et 
al., 2010; Kok et al., 1997; Merrill, 2002) . This pathway is initiated by condensation of serine 
with palmitoyl-CoA, and catalyzed by the rate-limiting enzyme serine palmitoyl transferase, 
resulting in the formation of 3-ketosphinganine. The latter is reduced in an NADPH-
dependent reaction by the enzyme 3-ketosphinganine reductase to sphinganine, which is 
then acylated into dihydroceramide by (dihydro)-ceramide synthases (Fig. 3) (Saddoughi et 
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al., 2008, van Echten-Deckert, 2006). A desaturation follows by the enzyme dihydroceramide 
desaturase (DES-1/DEGS-1) to insert a double bond between carbons 4-5 in the sphingosine 
backbone of dihydroceramide to generate ceramide (Michel et al., 1997). Ceramide 
synthases (Fig. 3) are also referred to as Lass (longevity-assurance homologue) family 
members. Six mammalian ceramide synthases have been identified molecularly, and each 
ceramide synthases protein exerts specificity for the generation of distinct endogenous 
dihydroceramides and ceramides with fatty-acid chain length specificity (Ogretmen, 2006; 
Pewzner-Jung et al., 2006). 
 
 
Ceramide is composed of a sphingoid base (18 carbons) and an amide linked fatty acid (14-26 carbons). 
Complex sphingolipids are composed of a hydrophilic head group (R) attached to the lipophilic ceramide 
backbone. These head groups may be phosphocholine in sphingomyelin or sugars in glycosphingolipids.  
Fig. 1. Bioactive sphingolipids. 
The de novo pathway is localized to the ER and continues in the Golgi apparatus where the 
enzymes glucosylceramide synthase and sphingomyelin synthase are localized (Pettus et al., 
2002) . Once ceramide is generated, it can be glycosylated by glucosylceramide synthase to 
form glucosylceramide on the cytoplasmic surface of Golgi. Glucosylceramide then serves as 
the precursor for glycosphingolipids. Ceramide may also be galactosylated to 
galactosylceramide by galactosylceramide synthase in the ER. Sulfatides and Gala-series 
glycosphingolipids are formed from galactosylceramide synthase. In turn, 
glycosphingolipids are hydrolyzed by ǃ-glucosidases and galactosidases to regenerate 
ceramide (Tettamanti, 2004). Gangliosides such as GD-2, are structurally and biochemically 
derived from lactosylceramide which is formed by transfer of a galactosyl residue to 
glucosylceramide. Sequential addition of one, two or three sialic acids to lactosylceramide 
results in formation of GM3, GD3 and GT3 (Bektas & Spiegel, 2004). In addition, ceramide 
can be converted into a number of other bioactive sphingolipids, including ceramide-1-
phosphate, sphingosine, and sphingosine-1-phosphate. 
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Ceramide is the central building block for complex sphingolipids. Enzymes are shown in italics.  
Fig. 2. Sphingolipid Metabolism. 
In the sphingomyelinase pathway, ceramide is generated from hydrolysis of sphingomyelin 
through the action of either acid or neutral sphingomyelinases (Clarke & Hannun, 2006; 
Marchesini & Hannun, 2004). These enzymes break down sphingomyelin to produce 
ceramide and phosphocholine, and are stimulated in response to TNF-ǂ (Luberto et al., 
2002; Schwandner et al., 1998), Fas ligand (Lin et al., 2000), or oxidative stress (Goldkorn et 
al., 1998). The sphingomyelinase mediated hydrolysis of sphingomyelin has emerged as a 
major pathway of stress-induced ceramide generation. Conversely, sphingomyelin synthase 
transfers the headgroup of phosphatidylcholine to ceramide and generates sphingomyelin 
and diacylglycerol in the process. This pathway has been suggested to regulate the levels of 
not only sphingomyelin and ceramide, but also diacylglycerol (Villani et al., 2008) as well as 
the activation of NFB (Hailemariam et al., 2008; Luberto et al., 2000).  
The sphingolipid recycling or salvage pathway refers to the various mechanisms of 
ceramide generation from the catabolism of complex sphingolipids which are broken down 
into sphingosine, which is then reused through reacylation to produce ceramide (Kitatani et 
al., 2008). This pathway involves a number of key enzymes that include sphingomyelinases, 
cerebrosidases, ceramidases, and ceramide synthases. It has been estimated to contribute 
from 50% to 90% of sphingolipid biosynthesis. Degradation of sphingolipids and 
glycosphingolipids takes place mostly in the acidic subcellular compartments, the late 
endosomes and the lysosomes. Sphingomyelin is converted to ceramide by acid 
sphingomyelinases. Ceramide can be deacylated with loss of the fatty acid from the amide 
bond through the action of acid ceramidases to yield sphingosine. Sphingosine can then 
translocate across the lysosome where it can be either re-acylated to ceramide or 
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phosphorylated by sphingosine kinase 1 or 2 to generate sphingosine-1-phosphate. 
Sphingosine-1-phosphate can be cleared by the action of specific phosphatases that 
regenerate sphingosine or by the action of a lyase that cleaves sphingosine-1-phosphate into 
ethanolamine-1-phosphate and a C16-fatty-aldehyde. 
 
 
Fig. 3. Ceramide Synthases. 
Ceramide synthases (CerS) acylate dihydrosphingosine to form dihydroceramide. In 
mammalian cells, each CerS protein exerts specificity for the generation of endogenous 
ceramides with distinct fatty-acid chain lengths. (Adapted from Ogretmen B, FEBS Lett, 2006) 
3. Role of sphingolipids in cancer cell proliferation, cell differentiation, 
senescence and apoptosis 
Sphingolipids play essential roles in cell growth, survival, and death (Birbes et al., 2002; 
Ogretmen & Hannun, 2004). These regulatory properties of sphingolipids allowed them to 
be extensively studied in cancer pathogenesis, cancer treatment, and multidrug resistance. 
In sphingolipid metabolism the precursors and products are biologically not inert, but they 
are effectors to mediate specific cell regulatory actions. These regulatory actions are 
mediated by interaction of sphingolipids with cell surface receptors, modulation of lipid 
rafts, and intracellular actions (Billich & Baumruker, 2008). The most studied bioactive 
sphingolipids are ceramide, ceramide-1-phospate, sphingosine, and sphingosine-1-
phosphate.  
3.1 Ceramide 
Ceramide exerts its downstream effects via activation of ceramide-activated serine–threonine 
phosphatases such as protein phosphates 1 and 2 (PP1 and PP2A) (Dobrowsky et al., 1993; 
Wolff et al., 1994) In addition, ceramide has been shown to activate PKCζ, the kinase KSR, and 
cathepsin D (Conway et al., 2000; Heinrich et al., 1999; Lozano et al., 1994). Different stimuli 
can activate ceramide formation. Chemotherapeutic agents such as daunorubicin, etoposide, 
camptothecin, fludarabine, and gemcitabine activate the de-novo pathway of ceramide 
generation. Other agents such as cytarabine, actinomycin D, etoposide, cisplatin (Biswal et al., 
2000; Bose et al., 1995; Chalfant et al., 2002; Gomez del Pulgar et al., 2002; Lacour et al., 2004; 
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Perry et al., 2000; Strum et al., 1994; Suzuki et al., 1997) actívate the sphinomyelinase pathways. 
TNF-, UV, and  radiation have been shown to activate sphingomyelinases (Haimovitz-
Friedman et al., 1994; Kim et al., 1991; Liu et al., 1998; Zhang et al., 2001) 
Ceramide has been widely implicated in the regulation of programmed cell death via 
numerous stimuli. Ceramide triggers apoptosis via mitochondrial, ER-stress and lysosomal 
pathways (Hannun & Obeid, 2011; Huang et al.; Mullen et al., 2011). Ceramide is able to 
induce G0/G1 cell cycle arrest by acting on different targets. It induces dephosphorylation 
of retinoblastoma (Rb) protein by the activation of protein phosphatase 1 (PP1) (Dbaibo et 
al., 1995; Jayadev et al., 1995; Kraveka et al., 2007). Additionally, ceramide specifically 
inactivates cyclin-dependent kinase 2 (CDK2) through dephosphorylation (Lee et al., 2000), 
or by up-regulation of CDK inhibitors p21 and p27 through activation of protein 
phosphatase 2A (PP2A) (Adibhatla & Hatcher, 2010). 
Ceramide also can be increased by administration of short chain cell-permeable ceramides 
(Huang et al., 2011; Ryland et al., 2011). However, the effect of systemic application of these 
exogenous ceramides is reduced due to precipitation and minimal membrane transport. 
Nanotechnology has been developed to encapsulate short-chain ceramides for systemic 
delivery. The nanotechnology includes nanoliposomes, nanocolloids, and nanodendrimers 
(Ryland et al., 2011). Encapsulation of the exogenous ceramides into nanoliposomes reduces 
the systemic side effects when applied via intravenous or intraperintoneal routes. 
Exogenous C2-ceramide treatment of neuroblastoma cell line SH-SY5Y induced apoptosis by 
inactivation of Akt and translocation of apoptosis-inducing factor (AIF) to the nucleus and 
neuronal cell death by a mitochondrial pathway (Kim et al., 2007).  
The involvement of ceramide in senescence is supported by the fact that ceramide levels 
increased in human fibroblasts as they became senescent. Additional studies showed that 
treatment of low-passage-number human fibroblasts with exogenous short ceramide was 
able to induce morphological and biological changes associated with senescence such as 
dephosphorylation of Rb protein and inhibition of cyclin dependent kinases. The underlying 
mechanisms for these changes were the inhibition of phospholipase D (PLD), diacylglycerol 
generation, and PKC activity (Venable et al., 1995). 
Our group has provided another direct link between ceramide and senescence by 
involvement of ceramide in the regulation of telomerase activity and telomere length 
(Kraveka et al., 2003). Telomeres contain long stretches of tandemly repeated 5’-TTAGGG-3’ 
sequences found at chromosome ends in mammals to protect chromosomes. Progressive 
shortening of telomeres during cell division triggers the onset of events leading to 
senescence and/or cell death. However, telomeres are more stable in immortalized and 
cancer cells. This stabilization is achieved by the activity of telomerase, an RNA-dependent 
DNA polymerase, whose activity is detected in most cancer cells, allowing them to escape 
senescence and acquire immortality. Treatment of human neuroblastoma cell lines, SK-N-
SH and SK-N-AS, with all trans retinoic acid (ATRA) inhibited telomerase activity and 
increased the endogenous levels of C24:0 and C24:1 ceramides). The relation between ceramide 
and telomerase was supported by the fact that treatment of cells with ATRA in the presence 
of myriocin, a serine palmitoyl transferase inhibitor, significantly blocked the accumulation 
of ceramide, and presence of myriocin prevented in part the inhibition of telomerase. 
Mechanistically, inhibition of telomerase by endogenous ceramide in response to ATRA 
treatment involved, at least in part, down-regulation of the expression of telomerase reverse 
transcriptase (hTERT) mRNA. The regulation of telomerase expression by ceramide involves 
the inactivation of c-MYC transcription factor through increased ubiquitin-proteasome-
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mediated proteolysis (Ogretmen et al., 2001). Additionally, ceramide mediates rapid 
shortening of telomeres, involving the inhibition of nuclear localization and the telomere-
binding function of glyceraldehydes-3-phosphate dehydrogenase (Sundararaj et al., 2004). 
These data suggest that ceramide is one of the upstream regulators of telomerase activity 
and telomere length and has a key role in induction of senescence.  
3.2 Dihydroceramide 
Dihydroceramide, an intermediate in de novo pathway, is synthesized from sphinganine. 
Dihydroceramides were thought to be biologically inactive. Previous studies on the 
biological activity of dihydroceramides using their short chain analogs concluded that 
dihydroceramides were inactive in inducing cell death and apoptosis (Ahn & Schroeder, 
2002; Bielawska et al., 1993; Sugiki et al., 2000). However, recent studies have shown 
dihydroceramides to be involved in important cellular responses such as cell cycle arrest, 
apoptosis, ceramide channel formation, autophagy, and oxidative stress (Idkowiak-Baldys 
et al., 2010; Kraveka et al., 2007; Signorelli et al., 2009; Stiban et al., 2006; Wang et al., 2008; 
Zheng et al., 2006). These studies indicate the significance of endogenous levels of 
dihydroceramides in cell regulatory processes, and they suggest that the enzyme 
dihydroceramide desaturase has the potential to regulate cell function through both 
ceramide and dihydroceramide their respective sphingolipid metabolites. We will discuss 
dihydroceramides more in depth later in the chapter. 
3.3 Sphingosine and sphingosine-1-phosphate 
Sphingosine, was the first bioactive sphingolipid to be identified (Hannun et al., 1986). It is 
the product of ceramide degradation by ceramidases, acts like ceramide to exerting 
apoptotic effects in multiple cell lines (Ekiz & Baran, 2010). Other studies also showed that 
sphingosine interferes with multidrug resistance mechanisms in cancer cells. These 
mechanisms were ineffective against sphingosine-induced cell death. Sphingosine interacts 
with protein kinase C (PKC), ERK, akt/Protein Kinase B (akt/PKB) to induce apoptosis 
(Chang et al., 2001; Jarvis et al., 1997). Additionally, sphingosine causes the release of 
cytochrome c from mitochondrial membrane followed by activation of caspases (Cuvillier et 
al., 2001). In murine Neuro-2A neuroblastoma cells, sphingosine induced differentiation 
(Riboni, et al., 1998).  
Sphingosine-1-phosphate acts not only as anti-apoptotic agent, but also is implicated in 
angiogenesis, adhesion, migration, and inflammation (Chalfant & Spiegel, 2005; van Echten-
Deckert & Herget, 2006). It can function as an extracellular first messenger and also as 
intracellular second messenger. Intracellularly, it serves as second messenger regulating 
calcium mobilization, cell proliferation and survival (Ling et al., 2011). Extracellularly, 
sphingosine-1-phosphate exerts most of its actions as a specific ligand for a family of nine G-
protein-couples receptors (GPCRs) called sphingosine-1-phosphate -R1-5 and Gpr63 
(Argraves et al., 2010), contributing to physiological and pathological processes such as 
angiogenesis which is a critical factor for tumor progression (Ling et al., 2011). 
Mechanistically, the proliferative effect of sphingosine-1-phosphate may be mediated by 
mitogen-activated protein kinase (MAPK) pathway (Shu et al. 2002). It also stimulates cell 
survival pathways, such as nuclear factor B (NF-B) (Xia et al., 2002) and the Akt/PI3K 
(Phosphatidylinositol 3-kinase) pathway (Banno et al., 2001). Growth factors and cytokines 
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including vascular endothelial growth factor (VEGF) and platelet derived growth factor 
(PDGF) induce spingosine kinase leading to elevation of sphingosine-1-phosphate. 
Sphingosine kinase-1 inhibition can sensitize cells toward the action of radiation, to 
ceramide, and to cytotoxic agents such as doxorubicin, etoposide, imatinib, and cicplatin 
(Billich & Baumruker, 2008). There are currently several sphingosine kinase-1 and 2 
inhibitors available and in development. Sphingosine kinase is an attractive target in cancer 
treatment because blockage of its product, sphingosine-1-phosphate inhibits proliferation 
and induces apoptosis in cancer cells (French et al., 2006). Another approach is the use of the 
anti-sphingosine-1-phosphate receptor monoclonal antibodies. These antibodies can induce 
tumor progression in murine xenograft and allograft models (Saddoughi et al., 2008). They 
also can prevent sphingosine-1-phosphate induced cell proliferation and the release of pro-
angiogenic cytokines. This pathway presents an important target for cancer treatment. 
3.4 Ceramide-1-phosphate 
Ceramide-1-phosphate, another product of ceramide by phosphorylation ceramide kinase 
(CERK), shows pro-survival effects by inducing DNA synthesis, blocking caspases, 
suppressing acid sphingomyelinase, and promoting phagasome formation (Chalfant & 
Spiegel, 2005; Gomez-Munoz, 2004; Gomez-Munoz et al., 1995; Gomez-Munoz et al., 2004; 
Hinkovska-Galcheva et al., 2005). It is involved in mast cell degranulation (Mitsutake et al., 
2004). It has been shown to also serve as an activator of cytosolic phospholipase A2 
(cPLA2a) (Pettus et al., 2004), and thus may function as a key regulator of eicosanoid 
synthesis. ATRA has been reported to inhibit CERK transcription in SH-SY-5Y 
neuroblastoma cells (Murakami et al., 2010) 
3.5 Glucosylceramide 
Glucosylceramides have proliferative effects and are implicated in the development of drug 
resistance in cancer cells (Lucci et al., 1998; Messner & Cabot, 2010; Ogretmen & Hannun, 
2004). Numerous studies showed that glucosylceramide synthase overexpression is 
associated with multidrug resistance in many cancers including breast cancer (Zhang et al., 
2011), leukemia (Xie et al., 2008) colon cancer (Liu et al., 2010b), and glioblastoma (Barth et 
al., 2010). One study showed that glucosylceramide synthase regulates MDR1 expression 
through cSrc and -catenin signaling (Liu et al., 2010b). In leukemia cells overexpression 
glucosylceramide synthase gene is correlated with Bcl-2 signal transduction (Liu et al., 
2010a). In glioblastoma and neuroblastoma cells, glucosylceramide synthase mediated drug 
resistance is via inhibition of NADPH oxidase (NOX), thus blocking ROS generation and 
limiting apoptosis (Barth et al., 2010). A new mixed-backbone oligonucleotide (MBO-
asGCS), that specifically suppresses overexpressed human glucosylceramide synthase gene, 
can restore drug sensitivity in multidrug resistant cancer cells leading to apoptosis 
(Patwardhan et al., 2009). Additionally, co-Inhibition of MRD1 gene and glucosylceramide 
synthase by siRNA can restore sensitivity in multidrug resistant breast cancer cells (Zhang et 
al., 2011). Inhibition of glucosylceramide synthase by 1-Phenyl-2-decanolyamino-3-
morpholino-1-propanol (PDMP) inhibited cell growth in murine neuroblastoma cells 
(Uemura et al., 1991). Taken together, these data suggest the involvement of 
glucosylceramide synthase in multidrug resistance and pharmacological targeting of 
glucosylceramide synthase is an important goal to restore sensitivity of multidrug resistant 
cancer cells to cytotoxic agents and improve their efficacy. 
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4. Ceramide levels and sphingolipid expression in cancer 
Total ceramide levels and the amounts of individual ceramide species have been shown to 
be altered in tumor samples. Total ceramide content was decreased in ovarian tumors 
compared to normal ovarian tissue (Rylova et al., 1998). High grade astrocytomas also had 
lower levels of ceramide (Riboni et al., 2002). Utilizing liquid chromatography/mass 
spectrometry (LC/MS) to identify individual ceramide species has yielded some interesting 
results. Defects in the ceramide synthase 1 dependent generation of C18-ceramide (Figure 3) 
have been implicated in the pathogenesis of squamous cell carcinomas of the head and neck 
(HNSCC) (Koybasi et al., 2004). The data showed that the levels of C16-, C24-, C24:1-ceramides 
were significantly elevated in the majority of tumor tissues compared to their normal 
tissues, while the levels of only C18-ceramide were significantly decreased. Further 
experiments showed that overexpression of ceramide synthase 1, which is responsible for 
C18- generation, resulted in the inhibition of HNSCC cell growth, and enhanced 
chemotherapy-induced apoptosis in UMSCC22A HNSCC cells in situ, and in HNSCC 
xenografts in vivo (Senkal et al., 2007). More recent work from Dr. Ogretmen’s group 
showed that knockdown of ceramide synthase 6/C16-ceramide induced endoplasmic 
reticulum stress-mediated apoptosis (Senkal et al., 2010). A study by Schiffmann 
(Schiffmann et al., 2009) measured endogenous ceramide levels in 43 malignant breast 
tumors and 21 benign breast biopsies via LC/MS. The levels of C16-, C24:1- and C24:0- 
ceramides were significantly elevated in malignant tumors as compared to benign and 
normal tissue. As expected, increased mRNA expression of ceramide synthases 2, 4, and 6 
was detected. In breast cancer elevated levels of C16 ceramide were associated with 
metastatic disease. 
In summary, these recent reports appear contradictory to many of the older cell-based 
studies in which in-vitro treatments with ceramide or agents that stimulate ceramide 
generation induced apoptosis. However, these newer studies suggest that the levels of 
specific ceramide species and/or the activity and expression enzymes of sphingolipid 
metabolism play an important role in cancer pathogenesis. These studies suggest a 
relationship between certain long-chain ceramides and malignant transformation 
(Ponnusamy et al., 2010; Ryland et al., 2011). Studies also suggest that de novo generated 
ceramides differing in their fatty acid chain length may have opposing roles in 
promotion/suppression of tumors. These facts show that the biological function of ceramide 
may vary by its carbon chain length. Studies are currently underway in our laboratory 
examining sphingolipid species content and expression of sphingolipid enzymes in 
“low/intermediate risk” and “high risk” neuroblastoma tumor samples.  
The cellular ratio of ceramide/sphingosine-1-phosphate determines the cell fate and 
response to chemotherapy. Several studies suggest that sphingosine-1-phosphate regulates 
survival, migration, and proliferation of cancer cells. Elevated sphingosine-1-phosphate 
levels are associated with resistance to apoptosis and poor prognosis in cancer (Ryland et al., 
2011). Lung, colon, kidney, breast, ovary, stomach, and uterine cancers showed increased 
levels of sphingosine kinase 1 protein and mRNA (Ogretmen & Hannun, 2004). Sphingosine 
kinase 2 overexpression has been reported in neuroblastoma (Li et al., 2011). 
Acid ceramidase, another enzyme in sphingolipid metabolism that hydrolyzes ceramide 
into sphingosine, may be dysregulated in some cancers. Acid ceramidase was overexpressed 
in leukemic T-cell large granular lymphocyte leukemia and its inhibition induced apoptosis 
www.intechopen.com
 
Neuroblastoma – Present and Future 162 
in these cells (Shah et al., 2008). One study showed that acid ceramidase was induced by 
genistein (a phytoestrogen isoflavone) contributing to growth in MCF-7 breast cancer cells 
(Lucki & Sewer, 2011). Daunorubicin treatment in hepatoma cell line increased acid 
ceramidase levels leading to protection of these cells from daunorubicin-induced apoptosis 
(Morales et al., 2007). Acid ceramidase overexpression lead to resistance of prostate cancer 
cells to chemotherapy and radiation. In these cells acid ceramidase overexpression was 
associated with increased autophagy and lysosomal density leading to higher resistance by 
rapidly metabolizing ceramide (Mahdy et al., 2009; Turner et al., 2011). These results 
demonstrate that inhibitors to sphingolipid pathway enzymes have great potential in the 
treatment of malignancies. 
5. The dihydroceramide desaturase enzyme: Implications for neuroblastoma 
therapy 
5.1 Desaturase enzymes 
Dihydroceramide desaturase family members, consisting of DES1 and DES2, belong to the 
desaturase/hydroxylase superfamily. Dihydroceramide desaturase 1, is encoded by DES1 
(degenerative spermatocyte homologue 1) gene, and it is myristoylated at N-terminus 
(Beauchamp et al., 2007)). A family of sphingolipid 4-desaturases (homologues of the 
Drosophila melanogaster degenerative spermatocyte gene-1 (des-1)) were identified via a 
bioinformatics approach (Ternes et al., 2002). These proteins contain three His-containing 
consensus motifs that are characteristic of a group of membrane fatty acid desaturases. The 
human homologue of des-1 is now referred to as DEGS-1, although it was first cloned in 1997 
and named as Membrane Lipid Desaturase (MLD) since its physiologic substrate was not 
determined at the time (Cadena et al., 1997). DEGS-1 is the only dihydroceramide 
desaturase reported to be present in human cells, and its mouse homologue (mDES1) was 
shown to have desaturase activity (Omae et al., 2004). hDES2, the human homologue of the 
mouse DES2 (mDes2) gene, like mDES2 has dihydroceramide hydroxylase activity 
(Mizutani et al., 2004). While mDES2 has been reported to have both desaturase and 
hydroxylase activity, no desaturase activity was detected in HEK 293 human embryonic 
kidney cells overexpressing hDES2 (Mizutani et al., 2004). DES2 is responsible for 
biosynthesis of phytosphingoglycolipids in the microvilli of intestinal epithelial cells, 
kidney, and skin (Omae et al., 2004).  
 
 
Dihydroceramide synthesized by de novo pathway is desaturated by the multi-enzyme complex 
consisting of a flavoprotein-containing cytochrome b5 reductase (Cb5R-Fp), a cytochrome (cyt) b5, and 
a desaturase. (Adapted from Geeraert L, et al., Biochem J 1997) 
Fig. 4. Dihydroceramide Desaturase Complex. 
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The dihydroceramide desaturase complex consists of flavin-containing cytochrome b5 
reductase, a heme-containing cytochrome b5, and a non heme-containing desaturase 
(Causeret et al., 2000; Geeraert et al., 1997). 
5.2 Role of dihydroceramide desaturase on cell growth, cell cycle, and endogenous 
ceramide and dihydroceramide levels in neuroblastoma 
We investigated the role of dihydroceramide desaturase as a key enzyme in the de novo 
pathway of ceramide generation using human neuroblastoma SMS-KCNR cells (Kraveka et 
al., 2007). This study included the use of a novel in situ assay for desaturase activity using 
pyridinum conjugated water-soluble dihydroceramide analogues. The dihydroceramidoid 
(C12-dhCCPS) was as substrate to measure the activity of the enzyme by monitoring the 
conversion of C12-dhCCPS to C12-CCPS via LC/MS. Our results showed that 
dihydroceramide desaturase was an active enzyme in neuroblastoma cells and the assay 
provided a powerful method to study the dihydroceramide desaturase activity and the 
effects of related inhibitors on dihydroceramide desaturase activity. 
The effect of dihydroceramide desaturase inhibition by siRNA on endogenous ceramide and 
dihydroceramides was studied. There was approximately a 13-fold increase of endogenous 
dihydroceramides whereas endogenous ceramides decreased by 25% compared to untreated 
cells. No significant changes were seen in other sphingolipids. Desaturase inhibition resulted 
in growth inhibition and cell cycle arrest at G0/G1. Phosphorylated Rb (pRb) is critical for cell 
cycle progression by regulating the G1/S phase restriction point, thus controlling entry into 
the S phase. There was more than 50% decrease in pRb in cells treated with dihydroceramide 
desaturase siRNA, whereas no change in total Rb level was seen. To determine the 
involvement of protein phosphate 1 or 2A (PP1 and PP2A) in Rb dephosphorylation, cells 
were pre-treated with either okadaic acid, a specific PP2A inhibitor, or tautomycin, a specific 
PP1 inhibitor. Tautomycin was able to inhibit Rb hypophosphorylation whereas okadaic acid 
showed minimal effect, indicating involvement of PP1.  
Next, the effect of the synthetic retinoid, N-(4-hydroxyphenyl)retinamide (4-HPR), also 
known as fenretinide, on dihydroceramide desaturase activity was studied. This retinoid 
had been reported to increase ceramide levels via de-novo synthesis within 6 hours of 
treatment (Wang et al., 2001). We therefore initially aimed at testing if the inhibition of 
DEGS-1 by siRNA would block the 4-HPR induced ceramide generation and the anti-tumor 
effects of 4-HPR. Previously, 4-HPR had been reported to generate ceramide. However, 
some of the limitations of these earlier studies were due to the method used for the 
quantitation of ceramide levels in which ceramide was measured by enzymatic or labeling 
methods where it was difficult to differentiate ceramide from dihydroceramide species. 
Sphingolipid levels were measured by LC/MS. Increasing concentrations of 4-HPR were 
directly proportional to increases in endogenous dihydroceramide levels. There was no 
elevation but rather a modest decrease in endogenous ceramide levels. All-trans-retinoic 
acid had no effect on desaturase activity. The in situ assay for desaturase activity showed 
inhibition of desaturase activity in cells treated with 4-HPR. There was no change in mRNA 
as well as protein levels of dihydroceramide desaturase indicating that 4-HPR may be a 
direct and/or posttranslational inhibitor of dihydroceramide desaturase.  
Indeed, we recently demonstrated that dihydroceramide desaturase is a direct in vitro target 
for fenretinide (see below) (Rahmaniyan et al., 2011). Taken together, these observations 
reveal that 4-HPR is a potent and rapid inhibitor of dihydroceramide desaturase which 
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induces dihydroceramide generation. In agreement with our study, it was recently reported 
that inhibition of dihydroceramide desaturase in cultured keratinocytes contributes to 
increases in dihydroceramide and phytoceramides while ceramide levels decrease (Brodesser 
& Kolter, 2011). Additionally, Wang et al showed that 4-HPR works synergistically with D-
erythro-N,N-dimethylsphingosine (DMS), a sphingosine kinase inhibitor, resulting in 
increased intracellular sphinganine and dihydroceramide (Wang et al., 2008).  
Furthermore, treament of 4-HPR with the synthetic sphingolipid protein kinase C inhibitor, 
l-threo-dihydrosphingosine (safingol) was synergistic in neuroblastoma, melanoma, prostate, 
ewings sarcoma, colon, breast, and lung cancer cell lines (Batra et al., 2004; Maurer et al., 
2000). Of importance for neuroblastoma is that neuroblastoma cell lines resistant to cis-
retinoic acid are sensitive to 4-HPR (Reynolds et al., 2000). Together with our findings, these 
data suggest that dihydroceramides have a novel biological function involving cell growth 
and cell cycle, and they may play a role as targets for cytotoxic agents in cancer cells.  
6. Dihydroceramide desaturase inhibitors 
6.1 Background on enzyme Inhibition 
Before discussing the inhibitors for dihydroceramide desaturase , it is helpful to review the 
basic biochemistry of enzyme kinetics and types of inhibition. In general, enzyme inhibitors 
mediate their inhibitory actions either via affecting the gene expression of the enzyme of 
interest or via posttranslational modification of the enzyme, which are an indirect effect. 
Another mode of inhibition is to act directly on the enzyme itself, for instance binding to the 
active center of the enzyme and thus blocking the activity. Direct acting inhibitors may 
inhibit the enzyme activity reversibly or irreversibly. The reversible inhibition is divided 
into competitive, non-competitive, and uncompetitive inhibition. In competitive inhibition 
the inhibitor and the substrate compete to bind to the pools of free enzyme molecules (Fig. 
5). While most likely inhibitor and substrate compete for a common binding pocket (i.e. 
active site), they could bind to separate sites on the enzyme molecule exerting a negative 
regulation on each other. Thus, the apparent Km value increases with increasing inhibitor 
concentrations, but the Vmax value stays constant at all inhibitor concentrations (Copeland, 
2005). The dissociation constant Km represents the substrate’s affinity for the enzyme and Ki 
represents the inhibitor's affinity for the enzyme. The smaller these values, the higher the 
binding’s affinity for the enzyme. A non-competitive inhibitor binds to both the free enzyme 
and the enzyme-substrate (ES) complex (Fig. 5). This type of inhibitor has two different 
dissociation constants, one for binary enzyme-inhibitor (EI) complex (Ki) and one for the 
ternary enzyme-substrate-inhibitor (ESI) complex (Ki). Thus, Vmax decreases with 
increasing inhibitor concentrations, but Km value depends on the values. If >1, the 
inhibitor binds preferentially to the free enzyme, and Km increases with increasing inhibitor 
concentrations. If <1 the inhibitor binds preferentially to the ES complex, and Km value 
decreases with increasing inhibitor concentrations. If =1, the inhibitor binds with equal 
affinity to both the free enzyme and the ES complex, thus the Km values is constant. Unlike 
competitive inhibitors, non-competitive inhibitors can’t be overcome by high substrate 
concentrations.  
An uncompetitive inhibitor binds exclusively to the ES complex (Fig. 5). The formation of ES 
complex augments the inhibitor affinity for the ES complex contributing to decreased 
apparent values of both Km and Vmax with increasing substrate concentrations. Irreversible 
inhibitors or inactivators are characterized by the formation of covalent bonds with enzyme 
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molecules. The rate of covalent bond formation (rate of enzyme inactivation) will be slow 
(Copeland, 2005). Thus, irreversible inhibitors display time-dependent inhibition. This is 
because the amount of active enzyme at a given concentration of irreversible inhibitor 
depends on pre-incubation time of the inhibitor with the enzyme. The inactivation rate of 
the system is determined by the pseudo-first-order rate constant Kobs (Adam et al., 2001; 
Copeland, 2005). Irreversible inhibitors form initially a reversible non-covalent complex 
with the enzyme (EI or ESI) and this then reacts to produce the covalently modified "dead-
end complex" EI*. The rate at which EI* is formed is called the inactivation rate or kinact. The 
binding and inactivation steps of this reaction are investigated by incubating the enzyme 
with inhibitor and assaying the amount of activity remaining over time. The activity will 
decrease in a time-dependent manner (Maurer & Fung, 2000). In this section some of the 
dihydroceramide desaturase inhibitors will be discussed which act directly or indirectly on 
the enzyme. 
 
 
Fig. 5. Types of Enzyme Inhibition. 
(A) Competitive inhibition, the enzyme (E) can bind either the substrate (S) or the inhibitor 
(I); (B) Non-competitive inhibition, the inhibitor can bind to both the free enzyme and ES 
complex; (C) Uncompetitive inhibition, the inhibitor binds only to the ES complex.  
6.2 Direct acting agents: Retinoids and ceramide analogues 
Retinoids are natural and synthetic derivatives of vitamin A which include all-trans retinloic 
acid (ATRA), 13-cis retinoic acid, (13-cis-RA), and 4-HPR. They have been used in 
neuroblastoma treatment due to their effects on cell differentiation, proliferation, and 
apoptosis (Formelli & Cleris, 2000; Reynolds, 2000; Reynolds & Lemons, 2001). Treatment 
with 13-cis retinoic acid is now standard of care for patients with high risk neuroblastoma 
following stem cell transplant (Matthay et al., 2009; Matthay et al., 1999). Some of retinoids 
mediate their effects through the binding to retinoic acid receptors (RAR) and retinoid X 
receptors (RXR). Their toxicity has limited their clinical use. For this reason, a large number 
of synthetic analogues of retinoids has been developed and used in pre-clinical and clinical 
settings (Villani et al., 2006). ATRA has been shown to modulate sphingolipid metabolizing 
enzymes. In a recent study, it has been shown that ATRA induces growth arrest in estrogen 
receptor-positive MCF-7 cells by increased ceramide levels through neutral 
sphingomyelinase-2. P70 ribosomal S6 kinase (S6K) was identified as downstream effector 
of ATRA and neutral sphingomyelinase-2. In the same study, ATRA contributed to 3-fold 
upregulation of dihydroceramide desaturase mRNA (Clarke et al., 2011). 4-HPR is a 
synthetic retinoid with low toxicity in humans compared to its parent compound ATRA. 
This difference is believed to be a result of the substitution of an amide-linked 4-
hydroxyphenyl moiety for the carbonyl functional group of ATRA (Fig 6). In addition, this 
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change markedly reduces 4-HPR’s binding affinity for nuclear retinoid receptors, 
supporting the fact that 4-HPR’s anticancer activity is independent of retinoid receptors 
(Hail et al., 2010). The hydroxyl functional group of 4-HPR has been demonstrated to have 
essential roles in 4-HPR-promoting cytotoxic effects. This functional group also mediates its 
uptake in cancer cells. In addition, the hydroxyl functional group of 4-HPR triggers ROS 
production by a mechanism requiring the mitochondrial enzyme dihydroorotate 
dehydrogenase, an enzyme associated with the mitochondrial electron transport chain and 
required for de novo pyrimidine synthesis. 
 
 
Fig. 6. The Chemical Structures of ATRA, cisRA, 4-HPR and its metabolites 4-oxo-4-HPR 
and 4-MPR.  
4-HPR has been used in clinical trials as chemopreventive and chemotherapeutic agent for 
various cancers including breast, prostate, head and neck, pancreas, oral leukoplakia, and 
neuroblastoma. 4-HPR reduced the incidence of contralateral breast cancer and ipsilateral 
breast cancer recurrence (Torrisi et al., 2001). At low levels, 4-HPR induces apoptosis; at higher 
levels it shows necrosis as well (Lovat et al., 2004). The precise mechanism of its apoptotic 
action is not fully understood. Unlike most retinoids, 4-HPR has low affinity for retinoid 
receptors and its mediated apoptosis is RAR independent (Mershon et al., 2007). 4-HPR 
induces alkaline ceramidase 2 leading to increased dihydrosphingosine (sphinganine) levels 
(Mao et al., 2010). Besides its ability to generate ROS (Jiang et al., 2011, Lovat et al., 2005), 4-
HPR may increase ceramide levels via induction of ceramide synthase (Fig. 7) (Jiang et al., 
2004; Wang et al., 2001) and acidic sphingomyelinase (Corazzari et al., 2005; Lovat et al., 2004) . 
4-HPR-enhanced ceramide is subsequently metabolized via glycosphingolipids and GD3 
synthase to the ganglioside GD3 which activates 12-lypoxygenase (12-LOX). 12-LOX then 
mediates ROS generation with subsequent growth arrest and DNA damage-inducible 
transcription factor GADD153 and the Bcl-2 related protein BAK (Fig. 7) (Lovat et al., 2005) 
resulting in release of cytochrome c and activation of caspases-9 and-3 and ultimately 
apoptosis. In addition, in neuroblastoma cells 4-HPR induces the proapoptotic gene BBC3, a 
BH3-only family member of Bcl-2, which initiates the mitochondrial apoptotic pathway (Wei 
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et al., 2005). All mentioned mechanisms are p53-independent, indicating that all cancers with 
p53 mutation are sensitive to cytotoxic effects of 4-HPR.  
4-HPR has a very broad range (0.7- 10 M) of cytotoxicity and may have different effects 
dependent on the concentration and type of cancer cell used (Formelli et al., 2008). In 
neuroblastoma cells, high concentrations of 4-HPR (>5 M) have been shown to induce 
apoptosis and necrosis (Wang et al., 2001a) while lower concentrations (< 3 M) of 4-HPR have 
been reported to induce G1-S arrest and hypophosphorylation of Rb (DiPietrantonio et al., 
1998; Kraveka et al., 2007; Wu et al., 2001). For neuroblastoma patients enrolled on a Phase I 
pediatric trial the mean plasma steady-state concentration on day 7 was as 9.9 mol/L with 
the maximal tolerated dosage of 2,475 mg/m2 per day (Villablanca et al., 2006). One of the 
difficulties with 4-HPR treatment in patients is its low absorption. Another more recent 
pediatric Phase I study using a new formulation of 4-HPR to improve bioavailability 
(4HPR/Lym-X-Sorb oral powder), reported the day 7 mean peak plasma concentrations to be 
19.7 μM at the recommended dose of 1700 mg/m2 per day (Marachelian et al., 2009). These 
doses safely achieved levels active against neuroblastoma in vivo with minimal toxicity. 
We recently determined that the enzyme dihydroceramide desaturase is a direct target for 4-
HPR in-vitro using rat liver microsomes as enzyme source (Rahmaniyan et al., 2011). 4-HPR 
inhibited the enzyme dihydroceramide desaturase in a time-dependent manner and a dilution 
experiment showed almost no recovery of the enzyme activity suggesting that 4-HPR may 
inhibit the dihydroceramide desaturase activity irreversibly (Rahmaniyan et al., 2011). 
Two major metabolites of 4-HPR have been identified: N-(4-methoxyphenyl)retinamide (4-
MPR) and 4-oxo-N-(4-hydroxyphenyl)retinamide (4-oxo-4-HPR). 4-MPR is an inactive 
metabolite (Fig 6) with no apoptotic effects that can be used in cancer cells as a biomarker to 
predict response of cells to 4-HPR (Mehta et al., 1998). 4-MPR has longer plasma half-life 
than 4-HPR indicating that 4-MPR and 4-HPR have distinct tissue uptake and metabolism 
(Hail et al., 2010). 4-oxo-4-HPR, a very active and polar metabolite, is able to inhibit 4-HPR 
resistant cell growth and to act synergistically with the parent drug (Tiberio et al., 2010). In 
ovarian carcinoma cells 4-oxo-4-HPR is formed by induction of CYP26A1 (Villani et al., 
2004). Mechanistically, 4-oxo-4-HPR induces cell cycle arrest at G2/M, increases ceramide 
levels, and caspase-dependent apoptosis (Villani et al., 2006). It generates ROS and causes 
mitotic arrest via inhibition of tubulin polymerization. ROS generation is independent from 
mitotic arrest and occurs earlier (Tiberio et al., 2010). In our in vitro model, we showed that 
4-oxo-4-HPR is also a direct inhibitor of dihydroceramide desaturase as well, exhibiting 
lower Ki and IC50 than 4-HPR, indicating that 4-oxo-4-HPR is more potent than the parent 
drug. 4-MPR showed only very little inhibitory effect on dihydroceramide desaturase 
activity (Rahmaniyan et al., 2011). 
Another direct inhibitor of dihydroceramide desaturase is ceramide analogue, C8-
cyclopropenyl-ceramide (C8CPPC or GT11) (Triola et al., 2001) which is a competitive 
inhibitor of dihydroceramide desaturase. It was used in our in vitro studies and served as 
positive control to validate the assay (Rahmaniyan et al., 2011). At higher concentrations, 
GT11 loses its specificity where it also inhibits serine palmitoyl transferase in cells but not in 
vitro. In addition, it inhibits sphingosine lyase activity contributing to sphingosine-1-
phosphate accumulation (Triola et al., 2004). Together, these data indicate that the enzyme 
dihydroceramide desaturase may be a direct target for chemotherapeutic agents and 
exploring the type of bonds in enzyme-inhibitor complex could be of further interest.  
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(A) Enhanced ceramide by activation of acid sphinomyelinase (ASMase) can lead to formation of 
gangliosides GM3 and GD3 resulting in reactive oxygen species (ROS) generation via 12-Lipoxygenase 
(12-LOX). ROS induces the transcription factor GADD153 and BAK protein resulting in mitochondrial 
apoptosis; (B) Dihydroorotate dehydrogenase (DHODH) is a required component for 4-HPR-mediated 
ROS generation in certain tissues resulting in mitochondrial apoptosis; (C) The proapoptotic gene BBC3, 
a BH-3 only protein member of Bcl-2 family, can mediate apoptosis in response to 4-HPR; (D) inhibition 
of dihydroceramide desaturase (DES) by 4-HPR accumulates dihydroceramides (dhCer) in cells 
resulting in cell cycle arrest at G0/G1 by a mechanism involving pRb; (E) Increased dihydrosphingosine 
resulting from activation of alkaline ceramidase-2 by 4-HPR can initiate apoptosis; (F) In addition to 
above mentioned in vivo mechanisms, 4-HPR also has an in vitro effects. In vitro enzyme assay using rat 
liver miocrosomes (RLM) as protein source for DES, dhCer-analogue as substrate, and NADH as 
cofactor demonstrates that 4-HPR inhibits the conversion of dhCer-analogue into ceramide supporting 
the fact that 4-HPR binds directly to the DES enzyme itself.  
Fig. 7. Sphingolipid Mediated Mechanisms of Action of Fenretinide (4-HPR): 
6.3 Indirect acting agents: Oxidative stress, celecoxib, and resveratrol 
Dihydroceramide desaturase activity can be modulated by oxidative stress contributing to 
accumulation of dihydroceramides (Idkowiak-Baldys et al., 2010). We have reported that 
H2O2, tert-butylhydroperoxide, and the intracellular ROS inducer menadione contribute to 
dihydroceramide desaturase inhibition in breast and lung cancers as well as neuroblastoma. 
In these cells, accumulation of dihydroceramides was observed with little change in 
ceramide levels. The in vitro assay using cell lysates obtained from cells treated with H2O2 
showed inactivation of dihydroceramide desaturase. However, in the direct in vitro assay 
using rat liver microsomes or cell homogenates, H2O2 did not show a significant effect on 
dihydroceramide desaturase activity indicating that H2O2 inhibits dihydroceramide 
desaturase indirectly. The multi-enzyme complex of dihydroceramide desaturase (Fig. 4) is 
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involved in coupled reactions responsible for electron transport from NADPH to terminal 
desaturase that reduces oxygen. However, NADPH is added to the reaction and is present 
in both RLMs and cell homogenates. These results suggest that dihydroceramide desaturase 
inhibition by H2O2 is mediated by modulating the redox status of the cell. 
Another indirect-acting dihydroceramide desaturase inhibitor is the COX-2 inhibitor 
celecoxib. Celecoxib has been reported to inhibit neuroblastoma growth and induce 
apoptosis (Chen et al., 2011; Ponthan et al., 2007). One study showed that treatment of 
various cancer cells with celecoxib has increased dihydroceramide species such as C16-, C24:0- 
and C24:1- dihydroceramidse by dihydroceramide desaturase inhibition, whereas very long 
chain ceramides such as C24:0- and C24:1-ceramides were decreased. The anti-proliferative 
effect of celecoxib were related to dihydroceramide desaturase inhibition which was COX-2-
independent (Schiffmann et al., 2009).  
Resveratrol is a natural product found in grape skin, red wine, cranberries, blueberries, and 
peanuts. It is a phytochemical with anti-oxidant, anti-inflammatory and cardioprotective 
properties. It also causes apoptotic effects on cancer cells, including neuroblastoma (Soto et 
al., 2011; van Ginkel et al., 2007). In leukemia cell line HL-60 the apoptotic effect is mediated 
by ceramide accumulation via induction of CerS/LASS genes and down-regulation of SK1 
and GCS genes (Cakir et al., 2011). Additionally, it induces autophagy in HGC-27 gastric 
cancer cells without apoptosis. In this study, autophagy was mediated by the inhibition of 
dihydroceramide desaturase (Signorelli et al., 2009) by resveratrol. However, our in vitro 
assay neither celecoxib or resveratrol inhibited dihydroceramide desaturase. They had some 
inhibition at higher concentrations, supporting the fact that both agents may act indirectly 
on the enzyme (unpublished observations). Additionally, photodynamic therapy (Separovic 
et al., 2009), -tocopherol (Jiang et al., 2004), and XM462 (Munoz-Olaya et al., 2008) may 
function as indirect inhibitors of dihydroceramide desaturase by modulating the redox 
status of the cells as in case of hydrogen peroxide.  
7. Conclusions and future directions 
In cancer cells there is an underlying defect in apoptosis due to either overexpression of 
anti-apoptotic genes, or mutations in pro-apoptotic genes (Ogretmen & Hannun, 2004) 
leading to escape of apoptotic signaling and ultimately tumorogenesis (Huang et al., 2011). 
Thus, cancer is a disease characterized by imbalance between cell division and cell death. 
(Corazzari et al., 2005). Ceramide, the central molecule of sphingolipids, has been identified 
as mediator for differentiation, cell cycle arrest, cellular senescence, and apoptosis. 
Dysregulated enzymes and metabolites in sphingolipid metabolism, are associated with 
development and pathogenesis of various types of cancers. Sphingolipid metabolism is 
characterized by interconversion of one metabolite into another. For instance, ceramide can 
be degraded by ceramidase into sphingosine, which is further phosphorylated into 
sphingosine-1-phosphate. This and other pathways in sphingolipid metabolism create a 
network regulating individual molecules. A dysregulation in this network by altered levels 
of bioactive metabolites and enzymes in cancer indicates the importance of sphingolipids in 
pathogenesis and progression of cancer (Ogretmen & Hannun, 2004).  
As discussed before, accumulating evidence shows involvement of sphingolipid signaling in 
development of human cancers. Angiogenesis is an essential factor for tumor growth and 
metastasis. The process of angiogenesis is regulated by many angiogenic factors, such as 
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VEGF (Eggert et al., 2000). In neuroblastoma, tumor vascularity correlates with an 
aggressive phenotype. It has been demonstrated that VEGF is highly overexpressed in 
neuroblastoma, which is associated with poor prognosis (Li et al., 2011). Sphingosine-1-
phosphate signaling pathway is known to be involved in angiogenesis, which shows a close 
interaction with VEGF (Heo et al., 2009). Li and colleagues found that spingosine kinase 2 is 
highly expressed in neuroblastoma cells and tissues. The product of this enzyme, 
sphingosine-1-phosphate, induces VEGF expression in neuroblastoma cells via HIF-1- 
independent pathway. The same study showed that among sphingosine-1-phosphate 
receptors, S1P-receptor 2 (S1P2) correlates with VEGF mRNA expression suggesting that 
S1P/S1P2/VEGF signaling pathway may promote neuroblastoma growth and angiogenesis. 
This observation was supported by the fact that blockade of sphingosine-1-phosphate 2 by 
sphingosine-1-phosphate antagonist JTE-013 resulted in inhibition of tumor growth and 
angiogenesis. Taken together, these data suggest that sphingolipid signaling pathway is 
involved in angiogenesis and poor prognosis in neuroblastoma and modulation of 
sphingolipid signaling pathway may provide an effective approach to control 
neuroblastoma. 
Neuroblastomas originate from embryonic neural crest tissue, and are characterized by 
failure in differentiation. Spontaneous regression may result from maturation of neoplastic 
cells into terminally differentiated ganglion cells. Neuroblastoma is known to undergo 
spontaneous regression by differentiation and apoptosis to a benign phenotype, almost half 
of cases are aggressive with tendency to metastasize. The ability of neuroblastoma to 
spontaneously regress through differentiation has generated considerable interest in agents 
to induce this important biological process (Lovat et al., 2000). Previous studies 
demonstrated that ceramide positively influences neurite outgrowth, which is one aspect of 
neuronal differentiation, either as a mediator of nerve growth factor signaling through p75 
in hippocampal neurons (Schultz & Larsson, 2004), or upon direct application to 
neuroblastoma cells in culture such as Neuro2a cells (Prinetti et al., 1997; Riboni et al., 1998; 
Riboni et al., 1995). Riboni and colleagues showed that agents such as ATRA, or conditions 
leading to increase in cellular ceramide levels contribute to neuroblastoma differentiation. 
ATRA induced ceramide increase was also augmented by exogenous administration of 
sphingomyelin, sphingosine, or L-serine. Additionally, ATRA contributed to activation of 
neutral sphingomyelinase. The resulting increase in ceramide content contributed to 
differentiation in neuroblastoma cells. Mechanistically, ceramide-induced differentiation has 
been mediated by PP2A. An isoform of protein kinase C (PKC), namely PKC was also 
shown to be involved in both ATRA and growth factor induced morphological changes 
during neuroblastoma differentiation (Schultz & Larsson, 2004). It was also shown that in 
Neuro2a cells, exogenously administered sphingosine can be rapidly metabolized by 
degradation or N-acylation, where N-acylation largely dominates over degradation. This 
results in increase cellular levels of ceramide and, consequently, in differentiation of 
neuroblastoma cells. These data suggest that ceramide is involved in the regulation of 
neuroblastoma differentiation, which may offer a new strategy in neuroblastoma treatment.  
Spontaneous regression may also result from programmed cell death or apoptosis. Schaefer 
and colleagues showed that ceramide treatment of five neuroblastoma cell lines results in 
apoptosis. Although these neuroblastoma cells express CD95 receptors (a TNF receptor 
family member), they are resistant to apoptosis stimulated by anti-CD95 antibody or by 
CD95 ligand. However, ceramide treatment of these cells leads to apoptosis, suggesting that 
ceramide may act downstream of the CD95-death inducing signaling complex (DISC) 
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(Schaefer et al., 2000). Ceramide is also able to induce apoptosis in neuroblastoma cells by 
inactivation of Akt pathway and translocation of apoptotic-inducing factor (AIF) from the 
mitochondria (Kim et al., 2007). Administration of short chain C2 ceramide to cultured 
neuroblastoma cells causes apoptosis by activation of intrinsic pathway (Movsesyan et al., 
2002). As reported before, dihydroceramide accumulation in neuroblastoma cells causes cell 
cycle arrest as a result of dihydroceramide desaturse inhibition (Kraveka et al., 2007). Taken 
together, these data provide evidence in support of a role of sphingolipids in neuronal 
apoptosis, which might result in spontaneous regression in neuroblastoma, and this will 
open a new avenue in the therapeutic treatment of neuroblastoma.  
A dynamic sphingolipid equilibrium has been described. This equilibrium is characterized 
by a balance between pro-apoptotic and pro-survival sphingolipids (Cuvillier et al., 1996; 
Fox et al., 2006), for example the balance between ceramide and sphingosine-1-phosphate. If 
this balance shifts to ceramide, it can lead to cellular death or cell cycle arrest. If it shifts to 
sphingosine-1-phosphate, it can result in cell proliferation. The regulation of ceramidases 
and sphingosine kinases may help to regulate the dynamic balance between these two 
metabolites. However, this may not sufficient because there are other sphingolipid 
metabolites such ceramide-1-phosphate and glycosphingolipids that are also in balance with 
ceramide. Thus, it is necessary to study all sphingolipid metabolites and their regulating 
enzymes. Processes, which enhance the intracellular accumulation of ceramide, will provide 
favorable pro-apoptotic outcome in chemotherapy. Yet another way to increase ceramide 
levels are to administer exogenous short chain ceramides and metabolic precursors of 
ceramide (palmitate, sphingosine, and C6-ceramide). These can be used in combination with 
chemotherapeutics to augment their effects. 
Dihydroceramide desaturase is an important enzyme that has the potential to modulate the 
dihydroceramide /ceramide ratio in the cell. However, the regulation of dihydroceramide 
desaturase activity has not been well characterized. Dihydroceramide had been considered 
primarily as an inactive precursor of ceramide. However, recent studies including our work 
have demonstrated that dihydroceramides have a novel biological functions including cell 
cycle arrest, apoptosis, ceramide channel formation, autophagy and oxidative stress. These 
studies indicate the significance of endogenous levels of dihydroceramides in cell regulatory 
processes, and they suggest that dihydroceramide desaturase has the potential to regulate cell 
function through both ceramide and dihydroceramide (Kraveka et al., 2007, Rahmaniyan et al., 
2011). These observations have implications for the mechanism of action of 4-HPR and for a 
potential role for dihydroceramide desaturase as a target for chemotherapeutic agents 
(Rahmaniyan et al., 2011). Thus, the development of new drugs which augment ceramide and 
dihydroceramide levels will induce cell toxicity and apoptosis in cancer cells. Inhibition of 
dihydroceramide desaturase is a novel target for cancer therapy. The balance of ceramides and 
dihydroceramides within a cell may be key to cancer cell proliferation.  
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working hard and fighting for the children stricken by this disease.
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